Calmark's instruments gets connected to journal systems
Calmark Sweden AB (publ) collaborates with Zafena AB to connect instruments to the hospital's record system. The update is expected to be launched in the spring of 2024.
Calmark collaborates with Zafena to be able to offer connection to the hospitals' IT systems. Zafenas offers the solution Zafena POC-Workstation, which is a flexible workstation, gateway and access point. The workstation stores response history and can print the result. The workstation can also communicate bidirectionally with medical record and lab data systems, which means that a workstation can, for example, receive a lab referral and send the result to the patient record.
"We are extremely satisfied that the technical solution that Zafena offers. The development of the hospitals' IT systems is fast and it has been a challenge for us. With Zafena's solution, we get a ready-made concept that already works with several systems in Sweden and is easy to expand. In addition, we have been given the opportunity to print and scan barcodes, which has also been a request from a number of customers," says Michael Lundh, CTO at Calmark.
"Our product has already gained great acceptance globally, but in markets with more developed healthcare, connection to medical records has long been a wish. I am happy that we can soon meet this and want to take the opportunity to thank Zafena for a professional treatment and good cooperation," says Anna Söderlund, CEO at Calmark.
Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.
For more information about Calmark Sweden AB, please contact:
Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se
www.calmark.se
Calmark Sweden AB is a medical technology company that manufactures and markets a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, is CE marked and measures the bilirubin level in whole blood for jaundice detection in newborns. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product offers a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.
Tags: